Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy
Season 3, Episode 31, Aug 20, 2020, 07:22 PM
In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.